<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75435">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01756144</url>
  </required_header>
  <id_info>
    <org_study_id>2012-005664-10</org_study_id>
    <nct_id>NCT01756144</nct_id>
  </id_info>
  <brief_title>rhBMP-2 vs Autologous Bone Grafting for the Treatment of Non-union of the Docking Site in Tibial Bone Transport</brief_title>
  <official_title>rhBMP-2 vs Autologous Bone Grafting for the Treatment of Non-union of the Docking Site in Tibial Bone Transport</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      When there is a bone defect, bone transport is used to bridge the defect. Frequently, the
      bone in the docking site (where the transported bone comes together) doesn't heal.

      The objective is to study the effectivity of rhBmp-2 (inductos) to stimulate bone healing,
      in order to find new techniques to treat non-union of long bones.

      The method of the study is a randomized controlled trial, to compare rhBMP-2 and autologous
      bone grafting in stimulating bone healing in the docking site.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Bone healing in the docking site</measure>
    <time_frame>up to 4 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>up to one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edema</measure>
    <time_frame>up to one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cancer</measure>
    <time_frame>up to one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bone Healing</condition>
  <condition>Bone Morphogenetic Proteins</condition>
  <condition>Bone Transport</condition>
  <arm_group>
    <arm_group_label>Autologous bone grafting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>autologous bone of the iliac crest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhBMP-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inductos, recombinant human bone morphogenetic protein</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rhBMP-2</intervention_name>
    <arm_group_label>Autologous bone grafting</arm_group_label>
    <arm_group_label>rhBMP-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients treated with bone transport (Ilizarov technique) and have non-union of the
             docking site, which is characterized by absence of bridging callus after two months
             of compression in the docking site.

        Exclusion Criteria:

          -  Allergy for inductos

          -  active growth,

          -  malignancy

          -  infection

          -  PAD

          -  pathological fracture
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 19, 2012</lastchanged_date>
  <firstreceived_date>December 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Dr Jan Vanderstappen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
